Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer

Cancer

Volumn 82, Issue 4, 1998, Pages 697-702

  Kigawa, Junzo ^a   Minagawa, Yukihisa ^a   Kanamori, Yasunobu ^a   Itamochi, Hiroaki ^a   Cheng, Xiusi ^a   Okada, Makoto ^a   Oishi, Tetsuro ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Cisplatin; Etoposide; Glutathione; Glutathione S transferase ; Ovarian carcinoma; Second line chemotherapy

Indexed keywords

CISPLATIN; ETOPOSIDE; GLUTATHIONE; GLUTATHIONE TRANSFERASE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CISPLATIN; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0032519814     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980215)82:4<697::AID-CNCR12>3.0.CO;2-T     Document Type: Article

References (22)

1. Muggia FM. Cisplatin update. Semin Oncol 1991; 8: 1-4.
2. Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer 1993; 72: 804-8.
3. Drlica K, Franco RJ. Inhibition of DNA topoisomerases. Biochemistry 1987; 27:2253-9.
4. Cain JM, Collins C, Peterdorf S, Figge DC, Tamimi HK, Greer BE, et al. Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. Am J Obstet Gynecol 1996; 174:1688-94.
5. Minagawa Y, Kigawa J, Ishihara H, Itamochi H, Terakawa N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant Hela cells. Jpn J Cancer Res 1994; 85:966-71.
6. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 15: 1559-64.
7. Andres PA, Velury S, Mann SC, Howell SB. Cis-Diammine-dichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48: 68-73.
8. Fujiwara Y, Sugimoto Y, Kasahara K, Bungo M, Yamakido M, Tew KD, et al. Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J Cancer Res 1990; 81:527-35.
9. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-Diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988; 48:5713-6.
10. Dulick DM, Fenslau C, Hilton J. Characterization of melphalan-glutathione adducts whose formation is catalyzed by glutathione transferases. Biochem Pharmacol 1986; 35:3405-9.
11. Kagen VE, Yalwich JC, Day BW, Goldman R, Gantchev TG, Stoyanovsky SO. Ascorbate is the primary reductant of phenoxyl radical of etoposide in the presence of thiols both in cell homogenates and in model systems. Chemistry 1994; 33: 9651-60.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
13. Owens CWI, Belcher RV. A colorimetric micro-method for the determination of glutathione. Biochem J 1965; 94:705-11.
14. Green JA, Robertson LJ, Clark AH. Glutathione S-transferase expression in benign and malignant ovarian tumors. Br J Cancer 1993; 68:235-9.
15. Mulder TPJ, Verspagett HW, Sier CFM, Roelofs HM, Ganesh S, Griffioen G, et al. Glutathione S-transferase pi in colorectal tumors is predictive for overall survival. Cancer Res 1995; 55: 2696-702.
16. Ribrag V, Massad L, Janot TF, Morizet J, Gouyette A, Chabot GG. Main drug-metabolizing enzyme systems in human non-Hodgkin's lymphomas sensitive or resistant to chemotherapy. Leukemia Lymphoma 1995; 18:303-10.
17. Hamaguchi K, Godwin AK, Yakushijii M, O'dwyer PJ, Ozols RF, Hamilton TC. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993; 53:5225-32.
18. Kido Y, Khokhar AR, Siddik ZH. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells. Biochem Pharmacol 1994; 47:1635-42.
19. Cheng X, Kigawa J, Minagawa Y, Kanamoril Y, Itamochi H, Okada M, et al. Glutathione S-transferase-π and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 1997; 79:521-7.
20. Peters WHM, Roelofs SHMJ. Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases. Cancer Res 1992; 52:1886-90.
21. Hadada S, Komada M, Furumoto H, Hirao T, Aono T. Expression of glutathione S-transferase-π in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994; 52:313-9.
22. Britten RA, Green JA, Warenius HM. Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents, Int J Radiat Oncol Biol Phys 1992; 24:527-31.